Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion

UCB SA

03/05/2026 18:17

PARIS, May 3 (Reuters) - Belgian biopharmaceuticals company UCB UCB.BR has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.

UCB will pay $2 billion in upfront payments and up to $200 million in potential future milestone payments for Candid Therapeutics, which is headquartered in California and is working on treatments for autoimmune diseases.

 (Reporting by Sudip Kar-Gupta
Editing by Tomasz Janowski)

 ((sudip.kargupta@thomsonreuters.com;))